⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →

Godrej Agrovet Ltd (GODREJAGRO)

Fast Moving Consumer Goods · FMCG · NSE · Updated 2 September 2026
By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings
₹654.05 ↓ 12.51% (1Y)

🎯 Key Takeaways

  • Godrej Agrovet is transitioning from a traditional agri-input player to a high-margin, B2C-focused agri-value chain company, with management prioritizing strategic capex, margin recovery in Crop Care, and expansion in Animal Nutrition and dairy. The company is in a growth phase driven by product innovation, geographic diversification (notably Bangladesh JV), and disciplined capital allocation targeting 16-18% IRR on integrated facilities.
  • Revenue grew 22.4% QoQ to ₹2,855 in Q1FY27.
  • ⚠️ Crop Care segment remains vulnerable to monsoon variability and commodity price volatility, with recovery dependent on timely product launches and mar
Market Cap
₹12,581
P/E Ratio
28.2
P/B Ratio
6.19
ROE
20.9%
ROCE
20.7%
Debt/Equity
0.72
Div Yield
1.68%
Promoter
67.7%
✨ Ask AI About GODREJAGRO 📊 Interactive Charts

📖 The Story

Godrej Agrovet is transitioning from a traditional agri-input player to a high-margin, B2C-focused agri-value chain company, with management prioritizing strategic capex, margin recovery in Crop Care, and expansion in Animal Nutrition and dairy. The company is in a growth phase driven by product innovation, geographic diversification (notably Bangladesh JV), and disciplined capital allocation targeting 16-18% IRR on integrated facilities.

⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →

📰 What's Happening

In Q1 FY27 (August 12, 2026 filing), consolidated sales rose 10% YoY to INR 2,852 crores, led by 12.6% growth in Animal Nutrition and 28.9% in Oil Palm, despite a 16.2% decline in Crop Care due to delayed monsoon. Management highlighted 29% YoY growth in Animal Nutrition segment result and 14.4% in Oil Palm, with dairy revenue up 11.4% on branded volume growth. Capex of INR300-350 crores is being phased over 3-4 quarters for integrated facilities targeting 16-18% IRR, with new products Ashitaka and Takai expected to drive Crop Care recovery in H2. Bangladesh JV showed double-digit growth, and revised Astec revenue guidance was raised to over 20% for the full year.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

MetricSep 2025Dec 2025Mar 2026Jun 2026
Revenue2,5672,7182,3332,855
Operating Profit15618681184
OPM %6.1%6.8%3.5%6.4%
Net Profit84110102128
EPS₹4.81₹5.97₹5.45₹6.99

Revenue growth has accelerated sequentially, with Q1 FY27 sales at INR 2,855 crores (up from INR 2,333 crores in Q4 FY26), supported by strong segmental performance and volume growth in dairy and branded products. Operating margins improved to 6.4% in Q1 FY27 from 3.5% in the prior quarter, reflecting better segment mix and cost efficiency, while net profit rose to INR 128 crores. This margin expansion aligns with management’s focus on high-ROCE initiatives and operational improvements, including working capital optimization (reduced to 25 days).

🔮 Management Outlook & What's Next

Management expects Crop Care recovery in Q3-Q4 FY27 driven by new product rollouts (Ashitaka and Takai), revised Astec revenue growth guidance of over 20% for the full year, and margin normalization following temporary advantages. Capex is being deployed in a disciplined, phased manner with no new investments beyond the INR300-350 crores planned for integrated facilities targeting 16-18% IRR. The company is prioritizing sustainable growth through B2C expansion in dairy and frozen chicken, with emphasis on value-added products and digital transformation.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

ItemMar 2025Mar 2025Mar 2026Mar 2026
Equity Capital192192192192
Reserves2,1782,1891,6181,840
Borrowings1,9231,3962,1591,468
Total Liabilities5,9855,5166,1056,170
Fixed Assets2,6192,5792,5272,749
Investments20313993122
Total Assets5,9855,5166,1056,170

The balance sheet shows a stable capital structure with equity of INR 192 crores and reserves at INR 1,840 crores as of March 2026, while borrowings declined to INR 1,468 crores from INR 2,159 crores in the prior period, indicating active deleveraging. Total assets stood at INR 6,170 crores, supporting growth initiatives without overleveraging. The reduction in net borrowings and improved working capital efficiency (25 days vs 39 days) reflects stronger cash flow management and operational discipline.

💰 Cash Flow Statement (₹ Cr)

ItemMar 2026
Operating+1,281
Investing-150
Financing-869
Net Cash Flow+262

👥 Shareholding Pattern

CategoryQ2FY26Q3FY26Q4FY26Q1FY27
Promoters67.5%67.7%67.7%67.7%
FII7.2%6.3%6.3%6.5%
DII5.2%5.4%5.9%5.3%
Public12.5%13.2%12.6%13.0%
# Shareholders1,13,0671,16,0981,11,3651,14,250

Promoter holding remains stable at 67.74% (Q1 FY27), with consistent stakeholder confidence. FII holding declined slightly to 6.48% from 7.21% (Q2 FY26), while DII increased to 5.28% from 5.17%, suggesting institutional interest is shifting toward non-promoter investors. The rise in shareholder count to 1,14,250 indicates broadening retail participation, supporting liquidity and governance scrutiny.

⚡ StockFin Pro Go Pro — bigger Radar, no daily limits Upgrade

⚖️ Peer Comparison — FMCG

Company MCap (₹ Cr) P/E ROCE ROE D/E
HINDUNILVR 4.69 L Cr 31.3 29.8% 30.7% 0.00
ITC 3.34 L Cr 16.8 36.0% 27.8% 0.03
NESTLEIND 2.78 L Cr 73.0 99.2% 73.9% 0.00
VBL 1.37 L Cr 40.6 21.5% 17.4% 0.10
BRITANNIA 1.25 L Cr 47.9 54.1% 51.1% 0.27
LENSKART 1.15 L Cr 173.3 11.9% 7.7% 0.03
MARICO 1.09 L Cr 57.3 54.2% 46.4% 0.08
TATACONSUM 1.02 L Cr 62.2 10.2% 8.0% 0.10
GODREJCP 92,112 48.1 17.8% 15.1% 0.33
DABUR 68,173 34.6 21.3% 17.1% 0.09

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Crop Care segment remains vulnerable to monsoon variability and commodity price volatility, with recovery dependent on timely product launches and market adoption. 2. Margin pressure in Oil Palm could emerge if input costs rise or palm oil prices soften, despite current growth. 3. Bangladesh JV profitability, while promising, introduces currency and regulatory risks that could affect consolidated earnings. 4. Execution risk in capex deployment — delays or cost overruns in integrated facility rollout could impact IRR targets and margin recovery timeline.

📋 Recent Filings

🧠 Analyst's Read

Godrej Agrovet is executing a clear transformation toward higher-margin, B2C agri-value chains with strong segmental tailwinds and disciplined capital allocation. The key watchpoints are the pace of Crop Care recovery and the contribution of new products and Bangladesh JV to consolidated earnings growth, which will determine whether margin expansion sustains beyond operational improvements.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

✨ Deep Dive with AI on GODREJAGRO

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GODREJAGRO files new disclosures

Track GODREJAGRO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GODREJAGRO — Free

Free account · 2 AI queries/day

⚡ StockFin Pro Go Pro — bigger Radar, no daily limits Upgrade

© 2026 StockFin.ai — AI-powered Indian stock research

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd